BusinessFibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)By Nasdaq OMXOct 18, 2017, 11:01 AM UTC
BusinessFibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDSBy Nasdaq OMXMar 31, 2017, 11:05 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
BusinessPositive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney DiseaseBy Nasdaq OMXMar 30, 2017, 11:02 AM UTC
